3,299
Participants
Start Date
November 30, 2001
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2013
docetaxel, doxorubicin, cyclophosphamide
TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
Docetaxel,doxorubicin, cyclophosphamide
AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
Sanofi-Aventis, Bridgewater
Sanofi-Aventis, Buenos Aires
Sanofi-Aventis, Macquarie Park
Sanofi-Aventis, Brussels
Sanofi-Aventis, Sarajevo
Sanofi-Aventis, São Paulo
Sanofi-Aventis, Sofia
Sanofi-Aventis, Laval
Sanofi-Aventis, Shanghai
Sanofi-Aventis, Bogotá
Sanofi-Aventis, Zagreb
Sanofi-Aventis, Nicosia
Sanofi-Aventis, Prague
Sanofi-Aventis, Cairo
Sanofi-Aventis, Tallinn
Sanofi-Aventis, Paris
Sanofi-Aventis, Berlin
Sanofi-Aventis, Kallithea
Sanofi-Aventis, Hong Kong
Sanofi-Aventis, Budapest
Sanofi-Aventis, Dublin
Sanofi-Aventis, Netanya
Sanofi-Aventis, Beirut
Sanofi-Aventis, México
Sanofi-aventis, Auckland
Sanofi-Aventis, Warsaw
Sanofi-Aventis, Porto Salvo
Sanofi-Aventis, Bucharest
Sanofi-Aventis, Moscow
Sanofi-Aventis, Jeddah
Sanofi-Aventis, Ljubljana
Sanofi-Aventis, Midrand
Sanofi-Aventis, Seoul
Sanofi-Aventis, Barcelona
Sanofi-Aventis, Taipei
Sanofi-Aventis, Montevideo
Sanofi-Aventis, Caracas
Lead Sponsor
Cancer International Research Group (CIRG)
OTHER
Sanofi
INDUSTRY